The FDA has approved the first-ever GLP-1 weight-loss pill, potentially revolutionizing obesity treatment for millions of Americans who’ve been waiting for alternatives to injectable medications.
Novo Nordisk’s once-daily semaglutide tablet — the oral version of its wildly popular Wegovy injection — could hit U.S. pharmacies as early as January, reports indicate. The 25 mg tablet is designed to “reduce excess body weight and maintain weight reduction long term,” according to a statement from the pharmaceutical giant.
The approval marks a significant milestone in treating obesity, which affects more than 100 million American adults. With a starting dose priced at approximately $149 per month, the pill offers a potentially more convenient and accessible option than injectable alternatives.
Expanding Treatment Options
For Novo Nordisk, this approval adds to a string of recent regulatory wins. In August, the company received accelerated FDA approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. “This is a major advance for a patient population with historically limited options,” noted regulators at the time.
The Danish pharmaceutical company isn’t resting on its laurels, either. It recently filed for FDA approval of CagriSema, a once-weekly shot combining semaglutide with cagrilintide. Early trials showed impressive results — a 22.7% average weight loss after 68 weeks.
“CagriSema has the potential to represent a meaningful step forward in the holistic treatment of obesity,” said Novo Nordisk Chief Executive Mike Doustdar.
Beyond Weight Loss: Cardiovascular Benefits
What’s perhaps most significant about these developments? The medication’s benefits extend beyond the scale. The FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who have obesity or are overweight.
In clinical trials, major adverse cardiovascular events occurred in just 6.5% of Wegovy participants compared to 8% on placebo — a meaningful difference for patients at risk.
“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research.
Could this pill format be the game-changer that obesity medicine has been waiting for? Many experts think so. The acceptance of the New Drug Application (NDA) for the oral formulation positions it to become the first oral GLP-1 medication specifically approved for chronic weight management.
Additional regulatory updates continue to refine the medication’s use. In March 2025, Novo Nordisk received FDA supplemental approval for revisions to Wegovy’s prescribing information, as documented in FDA correspondence.
For the millions struggling with obesity and its related health conditions, the approval of an oral GLP-1 option doesn’t just offer convenience — it represents the mainstreaming of obesity treatment in a form as familiar as a daily vitamin, potentially reducing stigma while expanding access to what has become one of the most transformative classes of medications in modern medicine.
